September 15, 2016
(Managed Care Magazine) – Mylan Pharmaceuticals––currently the target of public and congressional ire over its hefty price increases for the EpiPen––had the second-highest executive compensation among all U.S. drug and biotech firms during the past five years, according to a Wall Street Journal analysis. The big paydays are unusual in view of the company’s small size in the U.S. drug industry, where it is No. 11 by revenue, the article notes.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.